Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
09/02/2026
The USD/JPY fell by 1.00% intraday, now trading at 155.66.
Latest
3 m ago
Standard & Poor's: Downgrade Raizen to junk status, seventh grade.
4 m ago
UBS CEO: The Swiss response to the Swiss credit crisis was emotional.
6 m ago
The Food and Drug Administration (FDA) stated that a television commercial for Novo Nordisk's (NVO.N) new weight loss drug contains "false or misleading" claims about the weight loss effects of the drug, exacerbating the challenges faced by the pharmaceutical company recently. The FDA said that the TV commercial "misleadingly" implies that the oral form of Wegovy has advantages over other weight loss medications. In a letter to Novo Nordisk on February 5, the agency specifically questioned the claims of "living lightly" and "bright future" that appeared in the advertisement. "Furthermore, these claims misleadingly imply benefits beyond actual weight loss, such as emotional relief, reduced psychological burden, bringing hope or direction to patients' lives, positioning the drug as a solution to broader life challenges rather than a treatment for a specific disease," the FDA said.
7 m ago
Trump supports Nexstar's acquisition of Tegna.
8 m ago
UBS CEO: In the US market, we are willing to temporarily defer growth in order to improve efficiency. It is expected that the net assets in the US market will show positive growth momentum in the second half of the year.
See all latest
